Bedrocan's Danish facility and the quiet logic of jurisdictional redundancy

What was built

Bedrocan announced in January 2025 that its new Danish production site in Køge had passed a GMP inspection by the Danish Medicines Agency and received the certificate permitting cultivation to begin. The company put the facility's annual capacity at 2,300 kilograms and described it as built to mirror the production standards of its two Dutch sites.

By the company's own account the site was inaugurated in 2025 and supplies its full product portfolio to pharmaceutical distributors and medicine manufacturers internationally.

Why passing first time is the story

Bedrocan's model rests on standardisation: each variety genetically identical batch to batch, with a consistent cannabinoid composition, produced as an active pharmaceutical ingredient rather than as a consumer product. Weekly harvests, controlled environment, independent lab testing.

The interesting claim about Denmark is not the tonnage. It is that a process developed over decades in the Netherlands transferred to a different regulator's jurisdiction and satisfied inspection at the first attempt.

The fact that our Dutch knowledge and experience has been transferred 1-on-1 to another jurisdiction is evidence of an unparalleled level of professionalism.

The company's own timeline is worth reading

Bedrocan dates its founding to 1984, originally in controlled indoor cultivation of vegetables and herbs, with standardised quality-controlled cannabis seed development through the 1990s. It became the exclusive supplier to the Dutch medicinal cannabis programme in 2003, began international exports in 2007, and was awarded GMP in 2017. The Danish site is the most recent entry in that sequence.

What redundancy buys

European medical cannabis supply has repeatedly proved fragile at single points. Programmes that depend on one producer in one jurisdiction inherit that jurisdiction's regulatory timetable, and patients in a third country can find their prescriptions disrupted by an administrative decision they have no visibility into.

A second EU-GMP site in a second member state does not eliminate that exposure, but it changes its shape. For a company producing active pharmaceutical ingredients under a standardisation promise, being able to say the same product comes from two certified jurisdictions is a supply-chain argument as much as a commercial one.

LeafCurrent reports company facility claims as company claims. Capacity and certification statements here are drawn from Bedrocan's own published material.